Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPERPEEP: Individualized PEEP in ARDS
NCT04012073Phase 3Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2022
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Composite clinical outcome (ICU mortality, 60-day ventilator free days, AUC IL-6) at 72 hours. Started Nov 2022; status: terminated.
Beyond the preview
Go deeper on NCT04012073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04012073.